This study is in progress, not accepting new patients
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Summary
- Eligibility
- for people ages 15-80 (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
- ID
- NCT03926130
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 1158 people participating
- Last Updated